


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in this application.

Claims 1-12. (Canceled)

13. (Currently Amended) A method for increasing binding of FKBP12.6 to RyR2 in a subject, or limiting a decrease in the level of RyR2-bound FKBP12.6 in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:



wherein

$R_1 = H, OR', SR', NR', \text{alkyl, or halide, at position } \underline{2, 3, 4, \text{ or } 5} \text{ on the } \underline{\text{benzothiazepine}} \text{ phenyl ring;}$

$R' = \text{alkyl, aryl, or acyl;}$

$R_2 = H, \text{alkyl, alkenyl, or aryl;}$

$R_3 = H, \text{alkyl, alkenyl, or aryl;}$

$R_4 = H, \text{halide, alkenyl, carboxylic acid, or an alkyl containing halogen, O or S; and}$

$m = 0, 1, \text{ or } 2.$

Claim 14. (Canceled)

15. (Original) The method of claim 13, wherein the subject is a human.

Claim 16. (Canceled)


17. (Previously Presented) The method of claim 13, wherein the subject has a cardiac condition selected from the group consisting of cardiac arrhythmia, tachycardia, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac death and exercise-induced sudden cardiac death.

18. (Previously Presented) The method of claim 13, wherein the effective amount of the agent is one or more of:


- (a) from about 5 mg/kg/day to about 20 mg/kg/day,
- (b) an amount resulting in a plasma concentration of from about 0.02 μ M to about 1.0 μ M in the subject, or
- (c) an amount resulting in a plasma concentration of from about 300 ng/ml to about 1000 ng/ml in the subject.

Claims 19 – 24. (Canceled)

25. (Currently Amended) The method of claim 13, wherein the agent is




26. (Currently Amended) The method of claim 25, wherein the agent is



Claims 27 and 28. (Canceled)

29. (Currently Amended) A method for reducing the risk of sudden cardiac death, sustained ventricular tachycardia VT and non-sustained ventricular tachycardia VT in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:



(g)

wherein

$R_1 = \text{H, OR}', \text{SR}', \text{NR}', \text{alkyl, or halide, at position } \underline{2, 3, 4, \text{ or } 5} \text{ on the } \underline{\text{benzothiazepine}} \text{ phenyl ring;}$

$R' = \text{alkyl, aryl, or acyl;}$

$R_2 = \text{H, alkyl, alkenyl, or aryl;}$

$R_3 = \text{H, alkyl, alkenyl, or aryl;}$

$R_4 = \text{H, halide, alkenyl, carboxylic acid, or an alkyl containing halogen, O or S; and}$

$m = 0, 1, \text{ or } 2.$

30. (Currently Amended) The method of claim 29, wherein the agent is administered to a subject that has or is at risk of developing a condition is selected from the group consisting of cardiac arrhythmia, tachycardia, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac

death and exercise-induced sudden cardiac death.


Claims 31 and 32. (Canceled)

33. (Previously Presented) The method of claim 29, wherein the effective amount of the agent is one or more of:

- (a) from about 5 mg/kg/day to about 20 mg/kg/day,
- (b) an amount resulting in a plasma concentration of from about 0.02 μ M to about 1.0 μ M in the subject, or
- (c) an amount resulting in a plasma concentration of from about 300 ng/ml to about 1000 ng/ml in the subject.

34. (Canceled)

35. (Currently Amended) The method of claim 34, wherein the agent is



Claims 36 - 42. (Canceled)

43. (Previously Presented) The method of claim 29, wherein the subject is a human.

Claims 44 - 48. (Canceled)

49. (Previously Presented) The method of claim 13, wherein R_4 = alkenyl, carboxylic acid, or an alkyl containing I or Br; and m = 0 or 1.

50. (Currently Amended) The method of claim 13, wherein ~~R_4 = OR' at position 3 on the phenyl ring~~, $R' = \text{alkyl}$; $R_2 = \text{H}$; $R_3 = \text{H}$; and $m = 0$ or 1.

51. (Previously Presented) The method of claim 50, wherein R_4 = alkenyl, carboxylic acid, or an alkyl containing I or Br; and R' = methyl.

52. (Previously Presented) The method of claim 51, wherein $m = 0$; and R_4 = alkenyl or carboxylic acid.

Claims 53 and 54. (Canceled)


55. (Currently Amended) The method of claim 29, wherein R_4 = ~~alkenyl~~, carboxylic acid, ~~or an alkyl containing I or Br~~; and $m = 0$ or 1.

56. (Currently Amended) The method of claim 29, wherein R_4 = ~~OR'~~, at position 3 on the phenyl ring, $R' = \text{alkyl}$; $R_2 = \text{H}$; $R_3 = \text{H}$; and $m = 0$ or 1.

57. (Currently Amended) The method of claim 56, wherein R_4 = ~~alkenyl~~, carboxylic acid, ~~or an alkyl containing I or Br~~; and $R' = \text{methyl}$.

58. (Currently Amended) The method of claim 57, wherein $m = 0$; and R_4 = ~~alkenyl~~ or carboxylic acid.

59. (Currently Amended) A method for treating cardiac arrhythmia in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:



(g)

wherein

$R_1 = H, OR', SR', NR', \text{alkyl, or halide, at position 2, 3, 4, or 5 on the phenyl ring;}$

$R' = \text{alkyl, aryl, or acyl;}$

$R_2 = H, \text{alkyl, alkenyl, or aryl;}$

$R_3 = H, \text{alkyl, alkenyl, or aryl;}$

$R_4 = H, \text{halide, alkenyl, carboxylic acid, or an alkyl containing halogen, O or S; and}$

$m = 0, 1, \text{ or } 2.$

60. (Previously Presented) The method of claim 59, wherein the effective amount of the agent is one or more of:


(a) from about 5 mg/kg/day to about 20 mg/kg/day,

(b) an amount resulting in a plasma concentration of from about 0.02 μ M to about 1.0 μ M in the subject, or

(c) an amount resulting in a plasma concentration of from about 300 ng/ml to about 1000 ng/ml in the subject.

61. (Canceled)

62. (Currently Amended) The method of claim 59, wherein the agent is



63. (Previously Presented) The method of claim 59, wherein the subject is a human.

Claims 64 and 65. (Canceled)

66. (Currently Amended) The method of claim 59, wherein $R_4 = \text{alkenyl, carboxylic acid, or an alkyl containing I or Br;}$ and $m = 0$ or 1.


67. (Currently Amended) The method of claim 59, wherein $R_4 = OR'$ at position 3

on the phenyl ring, $R'_1 = \text{alkyl}$; $R_2 = \text{H}$; $R_3 = \text{H}$; and $m = 0$ or 1 .

68. (Currently Amended) The method of claim 67, wherein $R_4 = \text{alkenyl}$, carboxylic acid, or an alkyl containing I or Br; and $R'_1 = \text{methyl}$.

69. (Currently Amended) The method of claim 68, wherein $m = 0$; and $R_4 = \text{alkenyl}$ or carboxylic acid.

70. (New) A method for reducing the risk of sudden cardiac death, sustained ventricular tachycardia and non-sustained ventricular tachycardia in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:



(g)

wherein

$R_1 = \text{OR}'$ at position 3 on the phenyl ring;

$R'_1 = \text{alkyl}$;


$R_2 = \text{H}$;


$R_3 = \text{H}$;

$R_4 = \text{alkenyl}$ or an alkyl containing halogen; and


$m = 0, 1, \text{ or } 2$.

71. (New) The method of claim 70 wherein the compound is





72. (New) A method for treating cardiac arrhythmia in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:



(g)

wherein

R₁ = OR' at position 3 on the phenyl ring;

R' = alkyl;

R₂ = H;

R₃ = H;

R₄ = alkenyl or an alkyl containing halogen; and

m = 0, 1, or 2.

73. (New) The method of claim 72 wherein the compound is

